The incidence of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) in a single patient accounts for only 0.4 to 14% of all primary liver cancer. However, the prognosis of its intrahepatic cholangiocarcinoma (ICC) component is poor. We experienced a unique case of a sequentially developed cHCC-CC with adrenal metastasis as the primary presentation and a hidden primary hepatocellular carcinoma. A 65-year-old female with a history of jaundice and abdominal discomfort was diagnosed with S4 ICC measuring 5 cm in diameter, and characterized histologically as papillary adenocarcinoma with intraductal growth, but without any evidence of malignant hepatocyte. S4 segmentectomy with hepaticojejunostomy revealed no additional masses. A follow-up CT scan 3 months after surgery showed a right adrenal mass with markedly increased serum AFP (4950 ng/mL), which was treated with right adrenalectomy. Histopathology revealed a metastatic hepatocellular carcinoma testing positive for AFP, glypican-3, and hepatocytes, but negative for CD-10, inhibin-, EMA, S-100, and cytokeratin-7. Serum AFP level immediately plummeted to 4.1 ng/mL upon adrenal mass removal. A recurrent S7 liver mass was suspected 1 year later with serum AFP value of 7.6 ng/mL, and characteristic CT imaging of HCC. TACE was performed with good response. Adrenal metastasis may manifest as the primary focus of hepatocellular carcinoma in sequentially developed cHCC-CC patients with hidden primary HCC. cHCC-CC should be considered in the differential diagnosis of cholangiocarcinoma with elevated AFP. 
INTRODUCTION
A combined hepatocellular carcinoma-cholangiocarcnoma is a relatively rare disease entity, accounting for only 0.4-14% of all primary liver cancer. [1] [2] [3] [4] The classi- Surgical resection may still lead to intra-and extra-hepatic recurrence, which is a major concern. Although relatively common in hepatocellular carcinoma (HCC), metastasis to adrenal gland rarely occurs in intrahepatic cholangiocarcinoma (ICC) and combined HCC-CC (cHCC-CC). We experienced a unique case of sequentially developed cHCC-CC, classified as Allen Lisa A, with adrenal metastasis as the primary presentation and a hidden primary HCC.
CASE
Sixty-five years old female with a history of jaundice and abdominal discomfort with a high serum alpha-fetoprotein (AFP) and low serum chorioembryonic antigen (CEA) (532 ng/ml and 1.9 mg/dl, respectively). No evi- and RadioFrequency Ablation (RFA) procedures were then performed with favorable responses (Fig. 6 ). Early intra-and extra-hepatic recurrence was detected, warranting regular imaging surveillance as well as tumor marker follow-up studies. The incidence of extra-hepatic metastasis is around 13.5 to 42 %, 11, 12 including metastasis to adrenal glands (12%). 11 Presentation of a cholangiocellular component appeared to be a poor prognostic indicator. 13 Since both adrenal glands are almost always included in the scanning area, any changes in size and glandular characteristics may be visualized to detect adrenal incidentalinoma, 3 an adrenal tumor discovered fortuitously during imaging for other indications. 14 Possibility of malignancy increases with large tumor size, heterogeneous lesion and presence of peritoneal lymphadenopathy.
Because of the rich sinusioidal blood flow and its multiple arterial supplies, the adrenal gland is a potential site for metastasis. 15 The mechanism of extrahepatic metastasis from primary liver tumor to adrenal glands may involve a direct extension through exophytic growth or systemically through retroperitoneal venous system. 12 Poor differentiation of malignant lesions from benign adenoma remains a diagnostic challenge in the management of adrenal incidentalinoma. 16 The diagnosis of adrenal metastasis in our case was straightforward-based on the size of the lesion, history of previous malignancy, and low attenuation in pre-contrast study. However, percutaneous biopsy was indicated for accurate histopathological diagnosis, due to conflicting results based on initial preoperative diagnosis of cHCC-CC and postoperative histopathology of ICC.
The 5-year survival rate of HCC patients with resected adrenal metastasis was reported around 20% to 45%. 15 When compare to other modality or no treatment, adrenalectomy provides the highest survival (11.1 months, 5.7 months, 21.4 months, respectively). 17 Disease-free interval of less than 12 months is associated with poor survival. 15 Interestingly, we detected a sequentially developed cHCC-CC (Allen Lisa A), with adrenal metastasis as the first presentation of a hidden hepatocellular carcinoma.
Although S4 mass was cholangiocarcinoma, metastasis or recurrent mass showed HCC-like features. Tsalis et al. 
